{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:37:31Z","timestamp":1794314251192,"version":"4.9.0"},"reference-count":329,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1378\/chest.126.3_suppl.204s","type":"journal-article","created":{"date-parts":[[2004,9,21]],"date-time":"2004-09-21T18:47:46Z","timestamp":1095792466000},"page":"204S-233S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":883,"special_numbering":"S","title":["The Pharmacology and Management of the Vitamin K Antagonists"],"prefix":"10.1016","volume":"126","author":[{"given":"Jack","family":"Ansell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Poller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Bussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Hylek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.126.3_suppl.204S_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/bi00601a003","article-title":"Mechanisms of coumarin action: significance of vitamin K epoxide reductase inhibition","volume":"17","author":"Whitlon","year":"1978","journal-title":"Biochemistry"},{"key":"10.1378\/chest.126.3_suppl.204S_bib2","doi-asserted-by":"crossref","first-page":"11210","DOI":"10.1016\/S0021-9258(18)33742-6","article-title":"Evidence that warfarin anticoagulant action involves two distinct reductase activities","volume":"257","author":"Fasco","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.204S_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1988.tb03274.x","article-title":"The relationship between inhibition of vitamin K 1,2,3-epoxide reductase and reduction of clotting factor activity with warfarin","volume":"25","author":"Choonara","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0003-9861(88)90571-1","article-title":"Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3 epoxide: evidence for multiple pathways of hydroxyvitamin K formation","volume":"264","author":"Trivedi","year":"1988","journal-title":"Arch Biochem Biophys"},{"key":"10.1378\/chest.126.3_suppl.204S_bib5","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1073\/pnas.71.7.2730","article-title":"Vitamin K dependent modifications of glutamic acid residues in prothrombin","volume":"71","author":"Stenflo","year":"1974","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.204S_bib6","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1016\/S0021-9258(19)42259-X","article-title":"The mode of action of vitamin K: identification of \u03b3-carboxyglutamic acid as a component of prothrombin","volume":"249","author":"Nelsestuen","year":"1974","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.204S_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0005-2795(77)90155-6","article-title":"A spectrum of partially carboxylated prothrombins in the plasmas of coumarin treated patients","volume":"494","author":"Friedman","year":"1977","journal-title":"Biochim Biophys Acta"},{"key":"10.1378\/chest.126.3_suppl.204S_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0021-9258(18)89728-9","article-title":"The kinetics of activation of normal and gamma carboxy glutamic acid deficient prothrombins","volume":"260","author":"Malhotra","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.204S_bib9","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1016\/S0021-9258(17)33107-1","article-title":"Role of gamma-carboxyglutamic acid: an unusual transition required for calcium-dependent binding of prothrombin to phospholipid","volume":"251","author":"Nelsestuen","year":"1976","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.204S_bib10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0021-9258(19)75174-6","article-title":"Differentiation of metal ion-induced transitions of prothrombin fragment 1","volume":"252","author":"Prendergast","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.204S_bib11","doi-asserted-by":"crossref","first-page":"14969","DOI":"10.1016\/S0021-9258(18)66814-0","article-title":"Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid","volume":"261","author":"Borowski","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.204S_bib12","first-page":"990","article-title":"Osteocalcin and matrix Gla protein: vitamin K dependent proteins in bone","volume":"69","author":"Hauschka","year":"1989","journal-title":"Phys Rev"},{"key":"10.1378\/chest.126.3_suppl.204S_bib13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.nu.08.070188.003025","article-title":"Role of vitamin K-dependent proteins in bone metabolism","volume":"8","author":"Price","year":"1988","journal-title":"Annu Rev Nutr"},{"key":"10.1378\/chest.126.3_suppl.204S_bib14","first-page":"1599","article-title":"Protein S, a vitamin K-dependent protein is a bone matrix component synthesized and secreted by osteoblasts","volume":"130","author":"Maillard","year":"1997","journal-title":"Endocrinology"},{"key":"10.1378\/chest.126.3_suppl.204S_bib15","doi-asserted-by":"crossref","first-page":"13398","DOI":"10.1016\/S0021-9258(17)38734-3","article-title":"Sequence of the precursor to rat bone Y-carboxyglutamic acid protein that accumulated in warfarin-treated osteosarcoma cells","volume":"260","author":"Pan","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.204S_bib16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0022-3476(75)80986-3","article-title":"Congenital malformations associated with the administration of oral anticoagulants during pregnancy","volume":"86","author":"Pettifor","year":"1975","journal-title":"J Pediatr"},{"key":"10.1378\/chest.126.3_suppl.204S_bib17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0002-9343(80)90181-3","article-title":"Maternal and fetal sequelae of anticoagulation during pregnancy","volume":"68","author":"Hall","year":"1980","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib18","first-page":"19","article-title":"Oral anticoagulant drugs: pharmacokinetic aspects","volume":"15","author":"Breckenridge","year":"1978","journal-title":"Semin Hematol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev.me.27.020176.001333","article-title":"Vitamin K and other oral anticoagulant drugs","volume":"27","author":"O'Reilly","year":"1976","journal-title":"Annu Rev Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-197904010-00001","article-title":"Clinical pharmacokinetics of oral anticoagulants","volume":"4","author":"Kelly","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib21","series-title":"The new dimensions of warfarin prophylaxis: advances in experimental medicine and biology.","first-page":"205","article-title":"Warfarin metabolism and drug-drug interactions","author":"O'Reilly","year":"1986"},{"key":"10.1378\/chest.126.3_suppl.204S_bib22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00003088-200140080-00003","article-title":"Pharmacogenetics of warfarin elimination and its clinical implications","volume":"40","author":"Takahashi","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib23","series-title":"Managing oral anticoagulation therapy: clinical and operational guidelines (vol 1)","first-page":"29:1","article-title":"Pharmacology of warfarin and related anticoagulants","author":"Wittkowsky","year":"2003"},{"key":"10.1378\/chest.126.3_suppl.204S_bib24","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0140-6736(98)00326-2","article-title":"Genetic control of anticoagulation","volume":"353","author":"Mannucci","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1067\/mcp.2001.117444","article-title":"Individual variability in sensitivity to warfarin: nature or nurture","volume":"70","author":"Loebstein","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.204S_bib26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib27","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Influence of CYP2C9 genetic variants on the risk of overanticoagulation and of bleeding events during warfarin therapy","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.204S_bib28","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1749-6632.1968.tb11950.x","article-title":"Hereditary resistance to coumarin anticoagulant drugs in man and rat","volume":"151","author":"O'Reilly","year":"1968","journal-title":"Ann NY Acad Sci"},{"key":"10.1378\/chest.126.3_suppl.204S_bib29","first-page":"1229","article-title":"Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs","volume":"308","author":"O'Reilly","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/archinte.1985.00360030147025","article-title":"Hereditary warfarin resistance","volume":"145","author":"Alving","year":"1985","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1046\/j.1365-2141.1997.2213036.x","article-title":"Missence mutations at ALA-10 in the factor IX peopeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticaogulant therapy","volume":"98","author":"Oldenburg","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/cpt1974154424","article-title":"Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man","volume":"15","author":"Breckenridge","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.204S_bib33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cpt1974162348","article-title":"Studies on the optical enantiomorphs of warfarin in man","volume":"16","author":"O'Reilly","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.204S_bib34","first-page":"545","article-title":"Stereoselective interaction of phenylbutazone with 13C\/12C labelled racemates of warfarin in man [abstract]","volume":"37","author":"O'Reilly","year":"1978","journal-title":"Fed Proc"},{"key":"10.1378\/chest.126.3_suppl.204S_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/clpt.1986.3","article-title":"The warfarin-sulfinpyrazone interaction: stereochemical considerations","volume":"39","author":"Toon","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.204S_bib36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJM197608122950702","article-title":"The stereoselective interaction of warfarin and metronidazole in man","volume":"295","author":"O'Reilly","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJM198001033020106","article-title":"Stereoselective interaction of trimethoprim-sulamethazole with the separated enantiomorphs of racemic warfarin in man","volume":"302","author":"O'Reilly","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib38","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1172\/JCI107711","article-title":"Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone","volume":"53","author":"Lewis","year":"1974","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/clpt.1987.149","article-title":"Interaction of amiodorone with racemic warfarin and its separated enantimorphs in humans","volume":"42","author":"O'Reilly","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.204S_bib40","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.1981.00340040054017","article-title":"Lack of effect of fortified wine ingested during fasting and anticoagulant therapy","volume":"141","author":"O'Reilly","year":"1981","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib41","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/j.1875-9114.1997.tb03782.x","article-title":"A review of enzyme induction of warfarin metabolism with recommendations for patient management","volume":"17","author":"Cropp","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.126.3_suppl.204S_bib42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/s-0038-1661101","article-title":"Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins","volume":"51","author":"Bechtold","year":"1984","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.1983.03330250049027","article-title":"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration","volume":"249","author":"Weitkamp","year":"1983","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.204S_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM196201112660205","article-title":"Effect of sodium dextrothyroxine in patients receiving anticoagulants","volume":"266","author":"Owens","year":"1962","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib45","first-page":"309","article-title":"Studies on the interaction of warfarin and clofibrate in man","volume":"27","author":"O'Reilly","year":"1972","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1378\/chest.126.3_suppl.204S_bib46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cpt1979262145","article-title":"Commentary: hematological pertubations associated with salicylate","volume":"26","author":"Rothschild","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.204S_bib47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.279.9.657","article-title":"Acetaminophen and other risk factors for excessive warfarin anticoagulation","volume":"279","author":"Hylek","year":"1998","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.204S_bib48","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jama.279.9.702","article-title":"Acetaminophen and warfarin: undesirable synergy","volume":"279","author":"Bell","year":"1998","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.204S_bib49","first-page":"210","article-title":"Effect of erythromycin in patients receiving long-term warfarin therapy","volume":"8","author":"Weibert","year":"1989","journal-title":"Clin Pharm"},{"key":"10.1378\/chest.126.3_suppl.204S_bib50","first-page":"332","article-title":"Potentiation of warfarin anticoagulation by topical testosterone treatment","volume":"4","author":"Lorentz","year":"1985","journal-title":"Clin Pharm"},{"key":"10.1378\/chest.126.3_suppl.204S_bib51","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jama.1965.03090150019004","article-title":"Human sources and absorption of vitamin K in relation to anticoagulation","volume":"194","author":"Udall","year":"1965","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.204S_bib52","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/0002-8703(80)90625-0","article-title":"Bleeding during acetysalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement","volume":"99","author":"Dale","year":"1980","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.204S_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/28.1.46","article-title":"Interaction of ibuprofen and warfarin on primary haemostasis","volume":"38","author":"Schulman","year":"1989","journal-title":"Br J Rheumatol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3181\/00379727-142-36980","article-title":"Effects of pencillin G on platelet aggregation, release and adherence to collagen","volume":"142","author":"Cazenave","year":"1973","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM197408082910601","article-title":"The hemostatic defect produced by carbenicillin","volume":"291","author":"Brown","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib56","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib57","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0002-9149(83)90673-2","article-title":"Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole","volume":"51","author":"Chesebro","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib58","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199308193290802","article-title":"Aspirin and warfarin after heart-valve replacement: a comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement","volume":"329","author":"Turpie","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention is ischaemic heart disease in men at increased risk","volume":"351","author":"The Medical Research Council's General Practice Research Framework","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib60","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-121-9-199411010-00009","article-title":"The interaction of warfarin with drugs and food: a critical review of the literature","volume":"121","author":"Wells","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib61","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJM197108262850905","article-title":"Drug interactions with oral anticoagulants","volume":"285","author":"Koch-Weser","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1056\/NEJM197109022851005","article-title":"Drug interactions with coumarin anticoagulants","volume":"285","author":"Sellers","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1012742628628","article-title":"Drug interactions updates: drugs, herbs and oral anticoagulation","volume":"12","author":"Wittkowsky","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib64","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJM198007173030317","article-title":"Resistance to warfarin due to unrecognized vitamin K supplementation","volume":"303","author":"O'Reilly","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib65","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ajcn\/47.3.475","article-title":"Vitamin K deficiency from dietary vitamin K restriction in humans","volume":"47","author":"Suttie","year":"1988","journal-title":"Am J Clin Nutr"},{"key":"10.1378\/chest.126.3_suppl.204S_bib66","series-title":"Oral anticoagulants.","first-page":"9","article-title":"Structure and mechanism of activation of vitamin K antagnoists","author":"Sadowski","year":"1996"},{"key":"10.1378\/chest.126.3_suppl.204S_bib67","series-title":"The heart as a source of systemic embolisation","article-title":"Mechanisms of vitamin K metabolism and vitamin K-dependent hemostasis: Implications for warfarin therapy","author":"Bovill","year":"1992"},{"key":"10.1378\/chest.126.3_suppl.204S_bib68","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-0038-1655997","article-title":"Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with a constant vitamin K1 content","volume":"77","author":"Booth","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib69","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1126\/science.97.2518.313","article-title":"Influence of fever upon the action of 3,3-methylene bis-(4-hydroxoycoumarin)","volume":"97","author":"Richards","year":"1943","journal-title":"Science"},{"key":"10.1378\/chest.126.3_suppl.204S_bib70","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM198409063111007","article-title":"Warfarin: from bedside to bench","volume":"311","author":"Wessler","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib71","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1172\/JCI116814","article-title":"Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin-K dependent clotting factors","volume":"92","author":"Zivelin","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib72","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1203\/00006450-199605000-00014","article-title":"Decreased thrombin activity of fibrin clots prepared in cord plasma compared to adult plasma","volume":"39","author":"Patel","year":"1996","journal-title":"Pediatr Res"},{"key":"10.1378\/chest.126.3_suppl.204S_bib73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib74","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V75.2.344.344","article-title":"Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring anticoagulant therapy","volume":"75","author":"Furie","year":"1990","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.204S_bib75","first-page":"73","article-title":"The prothrombin time in haemophilia and in obstructive jaundice","volume":"109","author":"Quick","year":"1935","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.204S_bib76","first-page":"225","article-title":"Progress in standardisation in anticoagulant control","volume":"1","author":"Poller","year":"1987","journal-title":"Hematol Rev"},{"key":"10.1378\/chest.126.3_suppl.204S_bib77","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1657371","article-title":"Calibration of reference thromboplastins and standardisation of the prothrombin time ratio","volume":"49","author":"Kirkwood","year":"1983","journal-title":"Thromb Haemost"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib78","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib79","series-title":"33rd report: technical report series No. 687","author":"World Health Organization Expert Committee on Biological Standardization","year":"1983"},{"key":"10.1378\/chest.126.3_suppl.204S_bib80","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0022-2143(96)90014-1","article-title":"Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio","volume":"128","author":"Johnston","year":"1996","journal-title":"J Lab Clin Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib81","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0038-1642513","article-title":"Assessment of the validity of the INR system for patients with liver impairment","volume":"71","author":"Kovacs","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib82","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00001721-199907000-00001","article-title":"Clinically significant differences in the international normalized ratio measured with reagents of different sensitivities","volume":"10","author":"Lind","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib83","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1055\/s-0038-1651019","article-title":"The effect of some instruments for prothrombin time testing on the international sensitivity index (ISI) of two rabbit tissue thromboplastin reagents","volume":"62","author":"Poggio","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ajcp\/92.3.321","article-title":"Comparison of two automated coagulometers and the manual tilt tube method for determination of prothrombin time","volume":"92","author":"D'Angelo","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib85","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/jcp.42.1.97","article-title":"Effect of automation on the prothrombin time test in NEQAS surveys","volume":"42","author":"Poller","year":"1989","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib86","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1055\/s-0038-1645059","article-title":"The dependence of the international sensitivity index on the coagulometer used to perform the prothrombin time","volume":"63","author":"Ray","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib87","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/clinchem\/35.5.840","article-title":"Correction of instrument and reagent based differences in determination of the international normalised ratio (INR) for monitoring anticoagulant therapy","volume":"355","author":"van Rijn","year":"1989","journal-title":"Clin Chem"},{"key":"10.1378\/chest.126.3_suppl.204S_bib88","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/jcp.43.8.679","article-title":"Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers","volume":"43","author":"Thomson","year":"1990","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib89","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ajhp\/58.8.684","article-title":"Clinical impact of interlaboratory variation in international normalized ratio determinations","volume":"58","author":"Kinck","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1378\/chest.126.3_suppl.204S_bib90","first-page":"I","article-title":"Significant variation in the reporting of prothrombin time results despite utilization of the INR method of reporting [abstract]","volume":"100","author":"Jacobson","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.204S_bib91","first-page":"768","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy","volume":"122","author":"Fairweather","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib92","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/ajcp\/99.6.689","article-title":"Failure of the international normalized ratio to generate consistent results within a local medical community","volume":"99","author":"Ng","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib93","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/bmj.294.6581.1184","article-title":"Laboratory control of oral anticoagulants [editorial]","volume":"294","author":"Poller","year":"1987","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.204S_bib94","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0038-1647353","article-title":"Evaluation of international normalized ratios by a controlled field survey with 4 different thromboplastin reagents","volume":"64","author":"Kazama","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-0038-1651553","article-title":"Status of present and candidate International Reference Preparations (IRP) of thromboplastin for the prothrombin time: a report of the Subcommittee for Control of Anticoagulation","volume":"69","author":"van den Besselaar","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib96","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0038-1648816","article-title":"Effect of concentration of trisodium citrate anticoagulant on calculation of the international normalized ratio and the international sensitivity index of thromboplastin","volume":"72","author":"Duncan","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib97","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ajcp\/107.1.105","article-title":"Effect of 3.2% vs. 3.8% sodium citrate on routine coagulation testing","volume":"107","author":"Adcock","year":"1997","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib98","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/oxfordjournals.eurheartj.a060739","article-title":"Guidelines for prevention of thromboembolic events in valvular heart disease: Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology","volume":"16","author":"Gohlke-Barwolf","year":"1995","journal-title":"Eur Heart J"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib99","doi-asserted-by":"crossref","first-page":"220S","DOI":"10.1378\/chest.119.1_suppl.220S","article-title":"Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves","volume":"119","author":"Stein","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0002-9343(89)80690-4","article-title":"Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions","volume":"87","author":"Landefeld","year":"1989","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib101","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-118-7-199304010-00005","article-title":"Risk factors for complications of chronic anticoagulation. a multi-center study; Warfarin Optimized Outpatient Follow-up Study Group","volume":"118","author":"Fihn","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib102","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","article-title":"Optimal oral anticoagulant therapy in patients with mechanical heart valves","volume":"333","author":"Cannegieter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib103","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISOCOAT): Italian Study on Complications of Oral Anticoagulant Therapy","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib104","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","article-title":"An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation","volume":"335","author":"Hylek","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib105","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198212303072704","article-title":"Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis","volume":"307","author":"Hull","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib106","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0140-6736(88)92070-3","article-title":"Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement","volume":"1","author":"Turpie","year":"1988","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib107","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJM199002153220703","article-title":"Trial of different intensities of anticoagulation in patients with prosthetic heart valves","volume":"322","author":"Saour","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib108","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0022-5223(19)36724-8","article-title":"Comparison of two levels of anticoagulant therapy in patients with substitute heart valves","volume":"101","author":"Altman","year":"1991","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1378\/chest.126.3_suppl.204S_bib109","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","article-title":"Comparison of low-intensity warfarin therapy with conventional intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism","volume":"349","author":"Kearon","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib111","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.282.21.2058","article-title":"Oral anticoagulant therpay in patients with coronary artery disease: a meta-analysis","volume":"282","author":"Anand","year":"1999","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.204S_bib112","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1525-1497.2000.04329.x","article-title":"Prevention of thromboembolism in atrial fibrillation: a meta-analysis of trials of anticoagulants and antiplatelet drugs","volume":"15","author":"Segal","year":"2000","journal-title":"J Gen Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib113","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib114","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials","volume":"154","author":"Atrial Fibrillation Investigators","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","article-title":"A randomized trial of anticoagulants versus aspirin therapy after cerebral ischemia of presumed arterial origin","volume":"42","author":"The Stroke Prevention in reversible Ischemia trial (SPIRIT) Study Group","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib116","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1055\/s-0038-1665430","article-title":"Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy)","volume":"78","author":"Palareti","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib117","series-title":"Clinical epidemiology: a basic science for clinical medicine.","first-page":"283","author":"Sackett","year":"1991"},{"key":"10.1378\/chest.126.3_suppl.204S_bib118","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/0003-4819-76-3-112-6-423","article-title":"Very low doses of warfarin can prevent thrombosis in central venous catheters","volume":"112","author":"Bern","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib119","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0959-8049(97)89012-0","article-title":"A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy","volume":"33","author":"Nightingale","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1378\/chest.126.3_suppl.204S_bib120","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1365-2141.1998.00732.x","article-title":"Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies","volume":"101","author":"Boraks","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib121","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.303.6796.224","article-title":"Prevention of venous thrombosis with minidose warfarin after joint replacement","volume":"303","author":"Dale","year":"1991","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.204S_bib122","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.303.6796.219","article-title":"Efficacy of fixed minidose warfarin prophylaxis in total hip replacement","volume":"303","author":"Fordyce","year":"1991","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.204S_bib123","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/107602969500100404","article-title":"Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery despite inhibiting the postoperative rise in plasminogen activator inhibitor activity","volume":"1","author":"Poller","year":"1995","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib124","first-page":"703a","article-title":"A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer [abstract]","volume":"100","author":"Couban","year":"2002","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.204S_bib125","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archinte.158.14.1513","article-title":"Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (the AFASAK-2 study)","volume":"158","author":"Gullov","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib126","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)01180-X","article-title":"Randomized, double-blind trial of fixed low dose warfarin with aspirin after myocardial infarction","volume":"350","author":"Coumadin","year":"1997","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib127","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib128","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"323","author":"The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib129","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke Prevention in Atrial Fibrillation Study: final results","volume":"84","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1991","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.204S_bib131","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","author":"EAFT (European Atrial Fibrillation Trial) Study Group","year":"1993","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib132","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial","volume":"348","author":"Stroke Prevention in Atrial Fibrillation III Investigators","year":"1996","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib133","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","article-title":"Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial","volume":"360","author":"van Es","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib134","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib135","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/hc0502.103329","article-title":"Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study","volume":"105","author":"Fiore","year":"2002","journal-title":"Circulation"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib136","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1378\/chest.119.1_suppl.22S","article-title":"Managing oral anticoagulant therapy","volume":"119","author":"Ansell","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib137","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/106002809703100516","article-title":"Consensus guidelines for coordinated outpatient oral anticoagulation therapy management","volume":"31","author":"Ansell","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1378\/chest.126.3_suppl.204S_bib138","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-126-2-199701150-00006","article-title":"Comparison of 5 mg and 10 mg loading doses in initiation of warfarin therapy","volume":"126","author":"Harrison","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib139","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1161\/01.CIR.38.1.169","article-title":"Studies on coumarin anticoagulant drugs: initiation of warfarin therapy with a loading dose","volume":"38","author":"O'Reilly","year":"1968","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.204S_bib140","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archinte.159.1.46","article-title":"A randomized trial comparing 5 mg and 10 mg warfarin loading doses","volume":"159","author":"Crowther","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib141","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-138-9-200305060-00007","article-title":"Comparison of 10 mg and 5 mg warfarin initiation nomograms together with low molecular weight heparin for outpatient treatment of acute venous thromboembolism","volume":"138","author":"Kovacs","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib142","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1055\/s-0038-1657628","article-title":"Warfarin and heparin-induced skin necrosis and the purple toe syndrome: Infrequent complications of anticoagulant threatment","volume":"78","author":"Sallah","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib143","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1592\/phco.19.18.1385.30894","article-title":"Influence of warfarin regimen type on clinical and monitoring outcomes in stable patients in an anticoagulation management service","volume":"19","author":"Wong","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.126.3_suppl.204S_bib144","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/107602960100700108","article-title":"Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy","volume":"7","author":"Hixson-Wallace","year":"2001","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib145","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-116-11-901","article-title":"Aging and the anticoagulant response to warfarin therapy","volume":"116","author":"Gurwitz","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib146","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/ageing\/20.3.217","article-title":"The association of age with dosage requirement for warfarin","volume":"20","author":"Redwood","year":"1991","journal-title":"Age Ageing"},{"key":"10.1378\/chest.126.3_suppl.204S_bib147","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/jcp.45.8.704","article-title":"Factors affecting the maintenance dose of warfarin","volume":"45","author":"James","year":"1992","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib148","doi-asserted-by":"crossref","first-page":"878","DOI":"10.7326\/0003-4819-117-10-878","article-title":"Aging and warfarin therapy","volume":"117","author":"Mungall","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib149","first-page":"172","article-title":"Stereoselective dispostion of warfarin in young and elderly subjects [abstract]","volume":"55","author":"Bowles","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.204S_bib150","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1592\/phco.20.11.923.35260","article-title":"Evaluation of warfarin initiation regimens in elderly inpatients","volume":"20","author":"O'Connell","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.126.3_suppl.204S_bib151","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1008884004751","article-title":"Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use","volume":"7","author":"McCormick","year":"1999","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib152","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1023\/A:1013228718768","article-title":"Optimal frequency of patient monitoring and intensity of oral anticoauglation therapy in valvular heart disease","volume":"5","author":"Horstkotte","year":"1998","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib153","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1023\/A:1018778914477","article-title":"Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management","volume":"9","author":"Samsa","year":"2000","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib154","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/0272989X9201200206","article-title":"A model for planning optimal follow-up for outpatients on warfarin anticoagulation","volume":"12","author":"Kent","year":"1992","journal-title":"Med Decis Making"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib155","first-page":"676","article-title":"Frequent prothrombin time testing reduces inappropriate warfarin dose changes [abstract]","volume":"82","author":"Gunneman","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib156","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/archinte.158.5.528","article-title":"Evaluation of excessive anticoagulation in a group model health maintenance organization","volume":"158","author":"Lousberg","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib157","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-135-6-200109180-00008","article-title":"Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin","volume":"135","author":"Hylek","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib158","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0038-1655992","article-title":"Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy","volume":"77","author":"Makris","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib159","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2257.1998.00161.x","article-title":"Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal","volume":"20","author":"Nitu","year":"1998","journal-title":"Clin Lab Haematol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib160","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7326\/0003-4819-137-11-200212030-00009","article-title":"Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate","volume":"137","author":"Deveras","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib161","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(00)03125-1","article-title":"Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomized trial","volume":"356","author":"Crowther","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib162","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1055\/s-0038-1648371","article-title":"Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1","volume":"67","author":"Shetty","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib163","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5694\/j.1326-5377.1991.tb94070.x","article-title":"Anaphylactoid reactions and vitamin K [letter]","volume":"155","author":"Martin","year":"1991","journal-title":"Med J Aust"},{"key":"10.1378\/chest.126.3_suppl.204S_bib164","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1011237019082","article-title":"Anaphylactoid reactions to vitamin K","volume":"11","author":"Fiore","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib165","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1001\/archinte.158.19.2136","article-title":"Comparing different routes and doses of phytonadione for reversing excessive anticoagulation","volume":"158","author":"Whitling","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib166","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1001\/archinte.159.22.2721","article-title":"Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione","volume":"159","author":"Raj","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib167","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-137-4-200208200-00009","article-title":"Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy","volume":"137","author":"Crowther","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib168","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00001721-199304050-00010","article-title":"Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation","volume":"4","author":"Pengo","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib169","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-45-1-14","article-title":"The effectiveness of an oral vitamin K1 in controlling excessive hypoprothrombinemia during anticoagulant therapy","volume":"45","author":"Cosgriff","year":"1956","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib170","first-page":"453","article-title":"Small doses of vitamin K1 for correction of reduced prothrombin activity","volume":"34","author":"Shirger","year":"1959","journal-title":"Proc Mayo Clin"},{"key":"10.1378\/chest.126.3_suppl.204S_bib171","doi-asserted-by":"crossref","first-page":"959","DOI":"10.7326\/0003-4819-126-12-199706150-00005","article-title":"Correction of excessive anticoagulation with low dose oral vitamin K1","volume":"125","author":"Weibert","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib172","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.2001.03070.x","article-title":"A comparison of the efficacy and rate of response to oral and intreavenous vitamin K in reversal of over-anticoagulation with warfarin","volume":"115","author":"Watson","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib173","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199705223362107","article-title":"Management of anticoagulation before and after elective surgery","volume":"336","author":"Kearon","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib174","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","article-title":"Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses","volume":"89","author":"Cannegieter","year":"1994","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.204S_bib175","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1378\/chest.119.2.478","article-title":"How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage?","volume":"119","author":"Ananthasubramanian","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib176","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archinte.163.8.901","article-title":"Perioperative management of patients on oral anticoagulants: a systematic review","volume":"163","author":"Dunn","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib177","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/archinte.158.15.1610","article-title":"Dental surgery in anticoagulated patients","volume":"158","author":"Wahl","year":"1998","journal-title":"Arch Intern Med"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib178","doi-asserted-by":"crossref","first-page":"220S","DOI":"10.1378\/chest.119.1_suppl.220S","article-title":"Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves","volume":"119","author":"Stein","year":"2001","journal-title":"Chest"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib179","first-page":"534","article-title":"Usefulness of low molecular weight heparins during post-operative period in mitral mechanical valve replacement: clinical ischaemic and haemorrhagic complications in 110 cases [abstract]","volume":"19","author":"Berdague","year":"1998","journal-title":"Eur Heart J"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib180","first-page":"62","article-title":"Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin","volume":"62","author":"Johnson","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib181","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0002-9149(99)00341-0","article-title":"Use of enoxaparin for the chronically anticoagulated patient before and after procedures","volume":"84","author":"Spandorfer","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib182","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/01.CIR.101.10.1083","article-title":"Low molecular weight heparin after mechanical heart valve replacement","volume":"101","author":"Montalescot","year":"2000","journal-title":"Circulation"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib183","first-page":"301","article-title":"Is low molecular weight heparin a safe alternative to unfractionated heparin in patients with prosthetic mechanical heart valves who must interrupt antithrombotic therapy [abstract]?","volume":"21","author":"Ferreira","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.204S_bib184","first-page":"990","article-title":"Home LMWH bridge therapy in cardiac valve replacement: Safe, effective, and cost saving","volume":"35","author":"UPMC Health System","year":"2000","journal-title":"Formulary"},{"key":"10.1378\/chest.126.3_suppl.204S_bib185","first-page":"531A","article-title":"Outpatient anticoagulation protocol for mechanical valve recipients undergoing non-cardiac surgery [abstract]","volume":"135","author":"Galla","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib186","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1345\/aph.10305","article-title":"Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis","volume":"35","author":"Tinmouth","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1378\/chest.126.3_suppl.204S_bib187","first-page":"269","article-title":"A model for perioperative outpatient management of anticoagulation in high-risk patients: an evaluation of effectiveness and safety","volume":"54","author":"Wilson","year":"2001","journal-title":"Can J Hosp Pharm"},{"key":"10.1378\/chest.126.3_suppl.204S_bib188","doi-asserted-by":"crossref","first-page":"428A","DOI":"10.1016\/S0735-1097(02)81921-0","article-title":"Initiation of anticoagulation after cardiac surgery: a prospective cohort study of efficacy, safety, and cost with low molecular weight heparin bridging in lieu of continuous intravenous unfractionated heparin [abstract]","volume":"39","author":"Tsilimingras","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib189","unstructured":"Deleted in proof"},{"key":"10.1378\/chest.126.3_suppl.204S_bib190","first-page":"II-758","article-title":"Bridging therapy during temporary interruption of chronic anticoagulation is less costly with low molecular weigtht heparin than unfractionated heparin [abstract]","volume":"106","author":"Amorosi","year":"2002","journal-title":"Circulation"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib191","first-page":"360S","article-title":"Cost effectiveness and safety of outpatient enoxaparin bridge therapy [abstract]","volume":"116","author":"Smith","year":"1999","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib192","doi-asserted-by":"crossref","first-page":"234A","DOI":"10.1016\/S0735-1097(02)81044-0","article-title":"A prospective and randomized comparison of low molecular weight heparin and unfractionated heparin in chronically anticoagulated patients prior to cardiac catheterization [abstract]","volume":"39","author":"Omran","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib193","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1054\/ijom.2001.0172","article-title":"Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding","volume":"30","author":"Blinder","year":"2001","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1378\/chest.126.3_suppl.204S_bib194","first-page":"63","article-title":"Oral surgery in patients undergoing oral anticoagulant therapy","volume":"7","author":"Vicente Barrero","year":"2002","journal-title":"Med Oral"},{"key":"10.1378\/chest.126.3_suppl.204S_bib195","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJM198903303201305","article-title":"Hemostatic effect of tranexamic mouthwash in anticoagulant-treated patients undergoing oral surgery","volume":"324","author":"Sindet-Pedersen","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib196","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0278-2391(96)90297-9","article-title":"Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study","volume":"54","author":"Soute","year":"1996","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1378\/chest.126.3_suppl.204S_bib197","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients","volume":"117","author":"Rosove","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib198","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib199","first-page":"62","article-title":"Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant","volume":"99","author":"Sanfelippo","year":"2000","journal-title":"Wis Med J"},{"key":"10.1378\/chest.126.3_suppl.204S_bib200","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-127-3-199708010-00001","article-title":"Monitoring warfarin therapy in patients with lupus anticoagulants","volume":"127","author":"Moll","year":"1997","journal-title":"Ann Intern Med"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib201","first-page":"10","article-title":"Potential failure of the International Normalized Ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants","volume":"147","author":"Della Valle","year":"1996","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1378\/chest.126.3_suppl.204S_bib202","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/s-0037-1615146","article-title":"Control of oral anticoagulation in patients with the antiphospholipid syndorme: influence of the lupus anticoagulant on international normalized ratio","volume":"80","author":"Robert","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib203","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM199509073331016","article-title":"Thrombosis in the antiphospholipid antibody syndrome [letter]","volume":"333","author":"Rapaport","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib204","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1046\/j.1365-2141.1997.3283145.x","article-title":"Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome","volume":"98","author":"Lawrie","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib205","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody sndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib206","doi-asserted-by":"crossref","first-page":"552","DOI":"10.7326\/0003-4819-120-7-199404010-00004","article-title":"The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods","volume":"120","author":"Le","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib207","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00001721-199701000-00008","article-title":"Plasma levels of factors II, VII, and X and their relationship to the international normalized ratio during chronic warfarin therapy","volume":"8","author":"Lind","year":"1997","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib208","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1161\/01.CIR.88.2.454","article-title":"Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis","volume":"88","author":"Kornbert","year":"1993","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.204S_bib209","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199507063330102","article-title":"Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia","volume":"333","author":"European Atrial Fibrillation Trial Study Group","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib211","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(89)80689-8","article-title":"Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy","volume":"87","author":"Landefeld","year":"1989","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib212","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0002-9343(89)80690-4","article-title":"Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remedial lesions","volume":"87","author":"Landefeld","year":"1989","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib213","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archinte.1993.00410130073007","article-title":"Bleeding complications in oral anticoagulant therapy: an analysis of risk factors","volume":"153","author":"van der Meer","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib214","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-8703(82)90292-7","article-title":"Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio","volume":"103","author":"Forfar","year":"1982","journal-title":"Am Heart J"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib215","first-page":"42","article-title":"Patients highly unstable in their response to oral anticoagulants: a collaborative controlled study [abstract]","volume":"32","author":"Palareti","year":"2002","journal-title":"Pathophys Haemost Thromb"},{"key":"10.1378\/chest.126.3_suppl.204S_bib216","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0167-5273(88)90165-9","article-title":"Anticoagulation clinics and the monitoring of anticoagulant therapy","volume":"18","author":"Charney","year":"1988","journal-title":"Int J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib217","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1378\/chest.100.6.1553","article-title":"Low intensity anticoagulation in mechanical cardiac prosthetic valves","volume":"100","author":"Wilson","year":"1991","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib218","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","article-title":"Canadian atrial fibrillation anticoagulation (CAFA) study","volume":"18","author":"Connolly","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib219","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/B:THRO.0000011377.78585.63","article-title":"Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range","volume":"15","author":"Schmitt","year":"2003","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib220","first-page":"236","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"39","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib221","doi-asserted-by":"crossref","first-page":"272a","DOI":"10.1016\/S0735-1097(02)81220-7","article-title":"Comparison of narrow versus standard target INR ranges [abstract]","volume":"39","author":"Meier","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib222","first-page":"549","article-title":"The first months of oral anticoagulant treatment are associated with a very low quality of laboratory control: data from the Iscoat Study [abstract]","volume":"82","author":"Palareti","year":"1999","journal-title":"Thromb Haemost"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib223","first-page":"545","article-title":"Determinants of time spent in the therapeutic range while using vitamin k antagonists [abstract]","volume":"82","author":"Hutten","year":"1999","journal-title":"Thromb Haemost"},{"issue":"(suppl)1","key":"10.1378\/chest.126.3_suppl.204S_bib224","first-page":"86","article-title":"Therapeutic quality control of oral anticoagulant therapy comparing the short acting acenocoumarol and the long acting phenprocoumon [abstract]","author":"Gadisseur","year":"2001","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib225","first-page":"188","article-title":"A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol)","volume":"71","author":"Pattacini","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib226","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"Beyth","year":"1998","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib227","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2796.1991.tb00358.x","article-title":"Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients","volume":"229","author":"Launbjerg","year":"1991","journal-title":"J Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib228","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-0038-1651604","article-title":"Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic","volume":"69","author":"Cortelazzo","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib229","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4065\/70.8.725","article-title":"Bleeding and thromboembolism during anticoagulant therapy: a population based study in Rochester, Minnesota","volume":"70","author":"Gitter","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1378\/chest.126.3_suppl.204S_bib230","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0002-9343(93)90285-W","article-title":"Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention","volume":"95","author":"Landefeld","year":"1993","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib231","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1001\/archinte.1984.04400010074014","article-title":"Management of oral anticoagulant therapy: experience with an anticoagulation clinic","volume":"144","author":"Errichetti","year":"1984","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib232","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.410230607","article-title":"Complications of long-term anticoagulation","volume":"23","author":"Petty","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib233","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/j.1875-9114.1989.tb04128.x","article-title":"The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic","volume":"9","author":"Bussey","year":"1989","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.126.3_suppl.204S_bib234","first-page":"62","article-title":"Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction: second report of the Sixty Plus Reinfarction Study Research Group","volume":"I","author":"Sixty Plus Reinfarction Study Research Group","year":"1982","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib235","first-page":"42","article-title":"The performance of clinics for outpatient control of anticoagulation","volume":"21","author":"McInnes","year":"1987","journal-title":"J R Coll Physicians Lond"},{"key":"10.1378\/chest.126.3_suppl.204S_bib236","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/ageing\/17.6.388","article-title":"Long-term oral anticoagulant therapy in elderly patients","volume":"17","author":"Wickramasinghe","year":"1988","journal-title":"Age Ageing"},{"key":"10.1378\/chest.126.3_suppl.204S_bib237","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/pgmj.64.756.775","article-title":"Can old people on oral anticoagulants be safely managed as outpatients?","volume":"64","author":"Joglekar","year":"1988","journal-title":"Postgrad Med J"},{"key":"10.1378\/chest.126.3_suppl.204S_bib238","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0002-9343(94)90086-8","article-title":"Age-associated risks of prophylactic anticoagulation in the setting of hip fracture","volume":"96","author":"Issacs","year":"1994","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib239","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archinte.1977.03630140045012","article-title":"Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting","volume":"137","author":"Davis","year":"1977","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib240","first-page":"273","article-title":"Lack of excessive bleeding risk in elderly patients receiving long-term oral anticoagulation","volume":"3","author":"Graves","year":"1995","journal-title":"Cardiol Elderly"},{"key":"10.1378\/chest.126.3_suppl.204S_bib241","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.161.17.2125","article-title":"Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation","volume":"161","author":"Copland","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib242","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/archinte.1974.00320150060006","article-title":"Hemorrhagic complications of anticoagulant therapy","volume":"133","author":"Coon","year":"1974","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib243","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/archinte.1996.00440040081009","article-title":"Bleeding during antithrombotic therapy in patients with atrial fibrillation","volume":"156","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib244","doi-asserted-by":"crossref","first-page":"970","DOI":"10.7326\/0003-4819-124-11-199606010-00004","article-title":"The risk for and severity of bleeding complication in elderly patients treated with warfarin","volume":"124","author":"Fihn","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib245","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2796.1997.tb00023.x","article-title":"Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort","volume":"242","author":"Steffensen","year":"1997","journal-title":"J Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib246","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/archinte.160.4.470","article-title":"Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study","volume":"160","author":"Palareti","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib247","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0002-9343(86)90260-3","article-title":"Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage","volume":"81","author":"Pettiti","year":"1986","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib248","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0954-6820.1954.tb01741.x","article-title":"Local hemorrhage and necrosis of the skin and underlying tissues at starting therapy with dicumarol or dicumacyl","volume":"148","author":"Verhagen","year":"1954","journal-title":"Acta Med Scand"},{"key":"10.1378\/chest.126.3_suppl.204S_bib249","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0022-5347(17)51147-7","article-title":"Warfarin necrosis of the skin and subcutaneous tissue of the male genitalia","volume":"130","author":"Weinberg","year":"1983","journal-title":"J Urol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib250","first-page":"244","article-title":"Protein C and the development of skin necrosis during anticoagulant therapy","volume":"49","author":"Broekmans","year":"1983","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib251","doi-asserted-by":"crossref","first-page":"659","DOI":"10.7326\/0003-4819-104-5-659","article-title":"Successful warfarin anticoagulant despite protein C deficiency and a history of warfarin necrosis","volume":"104","author":"Zauber","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib252","first-page":"332","article-title":"Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulation treatment","volume":"51","author":"Samama","year":"1984","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib253","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/bmj.298.6668.233","article-title":"Necrosis of skin induced by coumarin in a patient deficient in protein S","volume":"298","author":"Grimaudo","year":"1989","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.204S_bib254","doi-asserted-by":"crossref","first-page":"589","DOI":"10.7326\/0003-4819-135-8_Part_1-200110160-00009","article-title":"Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis","volume":"135","author":"Warkentin","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib255","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/s-0038-1648869","article-title":"Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients","volume":"72","author":"Azar","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib256","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0002-9343(87)90697-8","article-title":"Significance of occult gastrointestinal bleeding during anticoagulation therapy","volume":"83","author":"Jaffin","year":"1987","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib257","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0002-9343(88)90105-2","article-title":"Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy","volume":"84","author":"Wilcox","year":"1988","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib258","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archinte.1994.00420060075008","article-title":"The significance of hematuria in the anticoagulated patient","volume":"154","author":"Culclasure","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib259","first-page":"791A","article-title":"Incidence and etiology of hematuria in patients on anticoagulant therapy [abstract]","volume":"37","author":"Caralis","year":"1989","journal-title":"Clin Res"},{"key":"10.1378\/chest.126.3_suppl.204S_bib260","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0022-5347(17)44295-9","article-title":"Clinical significance of hematuria in patients on anticoagulant therapy","volume":"137","author":"Schuster","year":"1987","journal-title":"J Urol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib261","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0022-5347(01)67469-X","article-title":"Anticoagulant associated hematuria: a prospective study","volume":"153","author":"van Savage","year":"1995","journal-title":"J Urol"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib262","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anticoaguants: mechanism of action, clinical effectiveness, and optimum therapeutic range","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.126.3_suppl.204S_bib263","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0002-9343(02)01131-2","article-title":"Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial","volume":"113","author":"Matchar","year":"2002","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib264","first-page":"846a","article-title":"Anticoagulant clinic vs family physician based warfarin monitoring: a randomized controlled trial [abstract]","volume":"96","author":"Anderson","year":"2000","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.204S_bib265","first-page":"2460","article-title":"Nine-year experience with a pharmacist-managed anticoagulation clinic","volume":"43","author":"Conte","year":"1986","journal-title":"Am J Hosp Pharm"},{"key":"10.1378\/chest.126.3_suppl.204S_bib266","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0002-9610(05)81015-3","article-title":"An outpatient anticoagulation protocol managed by a vascular nurse clinician","volume":"160","author":"Seabrook","year":"1990","journal-title":"Am J Surg"},{"key":"10.1378\/chest.126.3_suppl.204S_bib267","first-page":"304","article-title":"Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic","volume":"42","author":"Garabedian-Ruffalo","year":"1985","journal-title":"Am J Hosp Pharm"},{"key":"10.1378\/chest.126.3_suppl.204S_bib268","unstructured":"Deleted in proof"},{"key":"10.1378\/chest.126.3_suppl.204S_bib269","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/archinte.158.15.1641","article-title":"Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes, and health care costs","volume":"158","author":"Chiquette","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib270","first-page":"575","article-title":"Cost justification of a clinical pharmacist-managed anticoagulation clinic","volume":"19","author":"Gray","year":"1985","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1378\/chest.126.3_suppl.204S_bib271","first-page":"1","article-title":"Economic analysis of systematic anticoagulation management vs routine medical care for patients on oral warfarin therapy","volume":"2","author":"Campbell","year":"2000","journal-title":"Dis Manage Clin Outcomes"},{"key":"10.1378\/chest.126.3_suppl.204S_bib272","series-title":"Managing oral anticoagulation therapy: clinical and operational guidelines","first-page":"28:1","article-title":"Capillary whole blood prothrombin time monitoring: instrumentation and methodologies","author":"Ansell","year":"1997"},{"key":"10.1378\/chest.126.3_suppl.204S_bib273","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ajcp\/88.4.442","article-title":"A novel whole blood capillary technique for measuring prothrombin time","volume":"88","author":"Lucas","year":"1987","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib274","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0049-3848(92)90312-X","article-title":"Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor","volume":"66","author":"Yano","year":"1992","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.204S_bib275","first-page":"864","article-title":"Evaluation of a capillary whole blood prothrombin time measurement system","volume":"8","author":"Weibert","year":"1989","journal-title":"Clin Pharm"},{"key":"10.1378\/chest.126.3_suppl.204S_bib276","first-page":"611","article-title":"Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer","volume":"117","author":"Rose","year":"1993","journal-title":"Arch Pathol Lab Med"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib277","first-page":"869a","article-title":"Pilot study to determine use of a TAS analyzer in an anticoagulation clinic setting [abstract]","volume":"86","author":"Fabbrini","year":"1995","journal-title":"Blood"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib278","first-page":"112b","article-title":"Performance of the AvocetPTprothrombin time system [abstract]","volume":"92","author":"Ansell","year":"1998","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.204S_bib279","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1055\/s-0037-1613895","article-title":"A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods","volume":"83","author":"Gosselin","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib280","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1055\/s-0037-1614036","article-title":"A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin","volume":"84","author":"van den Besselar","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib281","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jcp.50.11.951","article-title":"Monitoring oral anticoagulant treatment with the TAS near patient test system: comparison with conventional thromboplastins","volume":"50","author":"Kitchen","year":"1997","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib282","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0049-3848(98)00098-X","article-title":"Accuracy of a portable international normalization ratio monitor in outpatients receiving long-term oral anticoagulant therapy: comparison with a laboratory reference standard using clinically relevant criteria for agreement","volume":"92","author":"Douketis","year":"1998","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.204S_bib283","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0049-3848(00)00323-6","article-title":"Accuracy of a portable prothrombin time monitor (CoaguChek) in patients on chronic oral anticoagulant therapy: a prospective multicenter study","volume":"100","author":"Cosmi","year":"2000","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.204S_bib284","first-page":"109","article-title":"Accuracy and precision of the LifeScan INR monitor in anticoagulation clinics","volume":"12","author":"Earp","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib285","first-page":"280","article-title":"Prothrombin measurement using a patient self-testing system: Oral Anticoagulation Monitoring Study Group","volume":"115","author":"Oral Anticoagulation Monitoring Study Group","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib286","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1309\/KM0J-G5V9-KCAG-CLEE","article-title":"Point-of-care prothrombin time measurement for professional and patient self-testing use","volume":"115","author":"Oral Anticoagulation Monitoring Study Group","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib287","first-page":"109","article-title":"Patient self-testing with the LifeScan INR monitor [abstract]","volume":"12","author":"Earp","year":"2001","journal-title":"J Thromb Thrombolysis"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib288","first-page":"863a","article-title":"Monitoring of oral anticoagulant therapy in pediatric patients using a new microsample PT device [abstract]","volume":"86","author":"Andrew","year":"1995","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.204S_bib289","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jcp.51.1.68","article-title":"Accuracy and precision of the TAS analyser for near-patient INR testing by non-pathology staff in the community","volume":"51","author":"Cachia","year":"1998","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib290","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/bmj.327.7405.5","article-title":"INRs and point of care testing","volume":"327","author":"Murray","year":"2003","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.204S_bib291","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/jcp.44.11.950","article-title":"Evaluation of the Cibra Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation","volume":"44","author":"Jennings","year":"1991","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib292","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archinte.1992.00400150103019","article-title":"Accuracy and precision of a portable anticoagulation monitor in a clinical setting","volume":"152","author":"McCurdy","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib293","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1055\/s-0038-1649700","article-title":"Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio?","volume":"70","author":"Tripodi","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib294","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1055\/s-0038-1657641","article-title":"Determination of the international sensitivity index of a new near-patient testing device to monitor oral anticoagulant therapy","volume":"78","author":"Tripodi","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib295","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/archinte.1995.00430170053006","article-title":"Accuracy of laboratory and portable monitor international normalized ratio determinations","volume":"155","author":"Kaatz","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib296","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1046\/j.0007-1048.2002.03361.x","article-title":"European concerted action on anticoagulation: multicentre international sensitivity index calibration of two types of point-of-care prothrombin time monitor systems","volume":"116","author":"Poller","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib297","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/jcp.56.2.114","article-title":"An assessment of lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood prothrombin time monitors","volume":"56","author":"Poller","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.204S_bib298","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/bmj.327.7405.30","article-title":"Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods","volume":"327","author":"Poller","year":"2003","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.204S_bib299","first-page":"291","article-title":"Point-of-care testing in coagulation and hemostasis: Implications for patient management","volume":"6","author":"Sickles","year":"1999","journal-title":"Dis Manage Health Outcomes"},{"key":"10.1378\/chest.126.3_suppl.204S_bib300","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-133-9-200011070-00010","article-title":"A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial","volume":"133","author":"Beyth","year":"2000","journal-title":"Ann Intern Med"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib301","first-page":"230","article-title":"Improvement of prognosis by home prothrombin estimation in patients with life-long anticoagulant therapy [abstract]","volume":"17","author":"Horstkotte","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.204S_bib302","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1010-7940(97)01204-9","article-title":"Self-management of oral anticoagulant therapy after heart valve replacement","volume":"11","author":"Hasenkam","year":"1997","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1378\/chest.126.3_suppl.204S_bib303","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.281.2.145","article-title":"A structured teaching and self-management program for patient receiving oral anticoagulation: a randomized controlled trial; Working Group for the Study of Patient Self-Management of Oral Anticoagulation","volume":"281","author":"Sawicki","year":"1999","journal-title":"JAMA"},{"key":"10.1378\/chest.126.3_suppl.204S_bib304","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0003-4975(01)02656-X","article-title":"International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous?","volume":"72","author":"Kortke","year":"2001","journal-title":"Ann Thorac Surg"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib305","doi-asserted-by":"crossref","first-page":"Q50","DOI":"10.1016\/S1520-765X(01)90043-4","article-title":"Additonal information from the GELIA database: analysis of benefit from self-management of oral anticoagulation (GELIA 6)","volume":"3","author":"Preiss","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.126.3_suppl.204S_bib306","doi-asserted-by":"crossref","first-page":"730","DOI":"10.7326\/0003-4819-111-9-730","article-title":"Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized, prospective study","volume":"111","author":"White","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib307","first-page":"111","article-title":"Anticoagulation therapy home and office monitoring evaluation study","volume":"12","author":"Kaatz","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib308","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.1995.00430200066010","article-title":"Long-term patient self-management of oral anticoagulation","volume":"155","author":"Ansell","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib309","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1055\/s-0037-1613888","article-title":"A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation","volume":"83","author":"Watzke","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib310","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(00)02470-3","article-title":"Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison","volume":"556","author":"Cromheecke","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib311","first-page":"(suppl)","article-title":"Comparison of the quality of oral anticoagulant therapy through patient self-management versus management by specialized anticoagulation cliniccs in the Netherlands [abstract]","volume":"86","author":"Gadisseur","year":"2001","journal-title":"Thromb Haemost"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib312","doi-asserted-by":"crossref","first-page":"Q65","DOI":"10.1016\/S1520-765X(01)90046-X","article-title":"Economic analysis of bleeding and thromboembolic sequelae after heart valve replacement (GELIA 7): the GELIA Study Group","volume":"3","author":"Muller","year":"2001","journal-title":"Eur Heart J"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib313","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1023\/A:1013276601930","article-title":"Anticoagulation management as a risk factor for adverse events: grounds for improvement","volume":"5","author":"Ansell","year":"1998","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib314","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/archinte.160.7.967","article-title":"Quality of anticoagulation management among patients with atrial fibrillation: results from a review of medical records from two communities","volume":"160","author":"Samsa","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib315","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.289.6442.422","article-title":"Computer assisted management of warfarin treatment","volume":"289","author":"Wilson","year":"1984","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.204S_bib316","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bmj.299.6709.1207","article-title":"Computer control of anticoagulant dose for therapeutic management","volume":"299","author":"Ryan","year":"1989","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.204S_bib317","first-page":"1529","article-title":"Computer control of anticoagulant dose [letter]","volume":"299","author":"Weston Smith","year":"1989","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.204S_bib318","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/jcp.46.4.299","article-title":"Prospective comparative study of computer programs used for management of warfarin","volume":"46","author":"Poller","year":"1993","journal-title":"J Clin Pathol"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib319","first-page":"S69","article-title":"A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy [abstract]","volume":"5","author":"Ageno","year":"1998","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.126.3_suppl.204S_bib320","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(98)04147-6","article-title":"The European Concerted Action on Anticoagulation (ECAA): multicentre randomized study of computerized anticoagulant dosage","volume":"352","author":"Poller","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.204S_bib321","first-page":"1060","article-title":"Effect of computer aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT","volume":"86","author":"Manotti","year":"2001","journal-title":"Haematologica"},{"key":"10.1378\/chest.126.3_suppl.204S_bib322","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1055\/s-0037-1613932","article-title":"A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy","volume":"83","author":"Ageno","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib323","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/bmj.319.7215.958","article-title":"Primary prevention of arterial thrombembolism in non-rheumatic atrial fibrillation in primary care: randomized controlled trial comparing two intensities of coumarin with aspirin","volume":"319","author":"Hellemons","year":"1999","journal-title":"BMJ"},{"key":"10.1378\/chest.126.3_suppl.204S_bib324","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1055\/s-0037-1614372","article-title":"Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists","volume":"82","author":"Hutten","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib325","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/archinte.1994.00420170093009","article-title":"Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice?","volume":"154","author":"Gottlieb","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib326","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2796.1989.tb00053.x","article-title":"Haemorrhagic and thrombembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis","volume":"225","author":"Lundstrom","year":"1989","journal-title":"J Intern Med"},{"key":"10.1378\/chest.126.3_suppl.204S_bib327","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study","volume":"343","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1994","journal-title":"Lancet"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.204S_bib328","first-page":"858","article-title":"Identification and surveillance of patients on oral anticoagulant therapy in a large geographic area-use of laboratory information systems","volume":"82","author":"Holm","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.204S_bib329","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJM199007193230302","article-title":"The effect of warfarin on mortality and reinfarction after myocardial infarction","volume":"323","author":"Smith","year":"1990","journal-title":"N Engl J Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215314926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215314926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:51:51Z","timestamp":1757919111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215314926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":329,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0012369215314926"],"URL":"https:\/\/doi.org\/10.1378\/chest.126.3_suppl.204s","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pharmacology and Management of the Vitamin K Antagonists","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.126.3_suppl.204S","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}